skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 16.11d (Release date: 2016-11-28)
SearchBox Top
SearchBox Bottom
Brentuximab Vedotin (Code C66944)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Brentuximab Vedotin

Definition: An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the chimeric anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.

Display Name: Brentuximab Vedotin

Label: Brentuximab Vedotin

NCI Thesaurus Code: C66944 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2932409  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Adcetris
ADC SGN-35
Anti-CD30 Antibody-Drug Conjugate SGN-35
Anti-CD30 Monoclonal Antibody-MMAE SGN-35
Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35
Brentuximab Vedotin
BRENTUXIMAB VEDOTIN
cAC10-vcMMAE
SGN-35

External Source Codes: 
CAS Registry Number 914088-09-8 (see NLM ChemIDplus info)
FDA UNII Code 7XL5ISS668
PDQ Closed Trial Search ID 530758
PDQ Open Trial Search ID 530758 (check for NCI PDQ open clinical trial info)
UMLS CUI C2932409

Other Properties:
Name Value (qualifiers indented underneath)
Accepted_Therapeutic_Use_For Hodgkin lymphoma; anaplastic large cell lymphoma (ALCL)
Chemical_Formula C68H106N11O15S
code C66944
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name SGN-35
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  

URL: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C66944

Mainbox Bottom